Published in Pharma Law Weekly, July 26th, 2005
The EARLY ACS trial design incorporates new technologies and reflects current treatment patterns in patients with non-ST elevation acute coronary syndromes (nSTE ACS) in a "real-world" setting. nSTE ACS is the term applied to unstable angina and non-ST elevation myocardial infarction (MI).
The trial is designed to provide important evidence regarding the potential benefit of initiating Integrilin, a potent glycoprotein (GP) IIb-IIIa inhibitor, early after patients present with high-risk acute...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.